Scott C Koenig

US Patent:

6368599, Apr 9, 2002

Filed:

Feb 22, 2000

Appl. No.:

09/510313

Inventors:

Solomon Langermann - Baltimore MD
Scott Koenig - Rockville MD
John Smit - Richmond, CA
Nilofer Qureshi - Madison WI

Assignee:

Univ. of British Columbia - Vancouver

International Classification:

A61K 3900

US Classification:

4241841, 4242831, 514 53, 514 54

Abstract:

The present invention provides immunogenic compositions and methods for inducing enhanced immune responses using an antigen by use of an adjuvant comprising a member selected from a Caulobacter (in particular, ) LPS or a fragment or derivative thereof.

US Patent:

6565849, May 20, 2003

Filed:

Mar 2, 2001

Appl. No.:

09/797760

Inventors:

Scott Koenig - Rockville MD

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

A61K 3942

US Classification:

4241471, 4241481, 4241491, 4241551, 4242041, 4242061, 4242081, 4242111, 4242261, 4242271, 4242341, 4242361, 4242771

Abstract:

Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.

US Patent:

6503511, Jan 7, 2003

Filed:

Apr 6, 1999

Appl. No.:

09/286981

Inventors:

Theresa M. Wizemann - Potomac MD
Scott Koenig - Rockville MD
Leslie S. Johnson - Germantown MD

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

A61K 3902

US Classification:

4241901, 4241841, 4242341, 4242371, 4242441, 530300, 530350, 514 2, 514 8

Abstract:

The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with pneumococcal derived polypeptides that include an alpha helix but exclude a choline binding region as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnositics and/or as protective/treatment agents for pathogenic bacterial species.

US Patent:

6689369, Feb 10, 2004

Filed:

Apr 27, 2001

Appl. No.:

09/844124

Inventors:

Scott Koenig - Rockville MD
Leslie S. Johnson - Germantown MD
John E. Adamou - Germantown MD

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

A61K 3909

US Classification:

4242441, 4241841, 4241851, 4241901, 530350

Abstract:

The present invention relates to novel immunogenic polypeptides, and therapeutically active fragments thereof, and vaccines, and vaccine compositions, for the prevention and treatment of streptococcal infection, especially by. The invention also relates to antibodies against the disclosed polypeptides, as well as methods of disease prevention and/or treatment.

US Patent:

6818216, Nov 16, 2004

Filed:

Nov 28, 2001

Appl. No.:

09/996288

Inventors:

James F. Young - Darnestown MD
Scott Koenig - Rockville MD
Leslie S. Johnson - Germantown MD

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

A61K 3921

US Classification:

4241591, 4242111, 4241301, 4241421

Abstract:

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.

US Patent:

6833356, Dec 21, 2004

Filed:

Aug 25, 2000

Appl. No.:

09/645835

Inventors:

Scott Koenig - Rockville MD
Jon Heinrichs - North Potomac MD
Leslie S. Johnson - Germantown MD
John E. Adamou - Germantown MD

Assignee:

Medimmune, Inc. - Gaithersburg MD

International Classification:

C07K 1400

US Classification:

514 12, 514 2, 530350, 4241841, 4241301, 4242431, 4242441, 536 231

Abstract:

The invention is directed to isolated polypeptides bearing sequence homology to the Sp36 protein found in pneumococcal organisms, such as. Polynucleotides encoding such polypeptides are also disclosed. The invention also relates to antibodies specific for the disclosed polypeptides and to uses of such antibodies in the treatment of diseases caused by staphylococci as well as group A and B streptococci. In addition, the invention relates to the use of the disclosed polypeptides in compositions and as vaccines and for prophylactic uses such as in vaccination of animals, especially humans, against a wide variety of streptococcal, staphylococcal and other diseases.

US Patent:

6855493, Feb 15, 2005

Filed:

Nov 28, 2001

Appl. No.:

09/996265

Inventors:

James F. Young - Potomac MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitis CA, US

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

C12Q001/70
A61K039/395

US Classification:

435 5, 4241301, 4242111

Abstract:

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.

US Patent:

6858706, Feb 22, 2005

Filed:

Apr 7, 1998

Appl. No.:

09/056019

Inventors:

Elaine I. Tuomanen - Germantown TN, US
Theresa M. Wizemann - North Potamac MD, US
H. Robert Masure - Germantown TN, US
Leslie Sydnor Johnson - Germantown MD, US
Scott Koenig - Rockville MD, US

Assignee:

St. Jude Children's Research Hospital - Memphis TN
MedImmune, Inc. - Gaithersburg MD

International Classification:

A61K038/00
A61K039/09
A61K039/38
A61K039/02
A61K039/00
C07K016/00
C07K017/00
C07K007/00
C07K005/00
C07K001/00

US Classification:

530350, 530324, 4241841, 4241851, 4241901, 4242441, 4242341

Abstract:

This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides a isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO 24, wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate.